TP53 and pancreatic neoplasm: A study showing gemcitabine-mediated tumor regression and p53-dependent gene expression increased the possibility that targeting the Bax-dependent cell death pathway, rather than the PUMA pathway, might result in significantly improved patient outcomes and prognosis in pancreatic cancer [49].